# Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

> **NCT05501756** · PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 60 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Cell Transplantation

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT05501756
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-11
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501756, "Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05501756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*